Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China-based Simcere Pharmaceutical Group has obtained GMP certification for its influenza vaccine production facility at Jiangsu Simcere Vaxtec Bio-Pharmaceutical, from the Chinese SFDA.
Subscribe to our email newsletter
Simcere Pharmaceutical holds 52.5% equity interest in Simcere Vaxtec subsidiary that expects to resume influenza vaccine production.
Separately, the company also announced the resignation of executive vice president Hong Zhao, effective 1 April 2013.
Simcere Pharmaceutical specializes in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China.